Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III ...
Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...
The Amazing Times on MSN5 小时
Five Common Medications That May Increase Your Risk of Dementia
Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...
来自MSN5 小时
Spear Bio secures FDA breakthrough device designation for its novel pTau 217 blood test ...
Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.
Medscape6 小时
Updated Alzheimer’s Guidelines Chart the Full Diagnostic Journey
Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...
Daily Independent17 小时
With severe dementia, medications are of limited benefit
The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...
Focused ultrasound machine can stop Parkinson's tremors
Delray Medical Center cut the ribbon on its newest high-tech machine last week that targets brain areas to treat movement ...
punjabnewsexpress1 天
Costly therapies to foster Alzheimer’s market growth globally: Report
New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...
clinicaltrialsarena6 天
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...